{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-000467","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.230485+00:00","generated_at":"2026-06-07T00:35:52.038019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Catheter Precision reports preliminary 2023 revenue $442K, net loss $72.4M including $61M goodwill impairment","bullets":["Q4 2023 revenue ~$129K; full-year revenue ~$442K.","Preliminary net loss: Q4 ~($2.5M), FY ~($72.4M) includes $61M one-time goodwill impairment.","Cash on hand $3.6M; shareholders equity $19.4M as of Dec 31, 2023.","Launched LockeT closure product; enrolled 100+ patients in Phase I study; IRB approved Phase II.","VIVO active in six European countries; IP portfolio expanded to 50 patents worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-000467","json":"https://secwatch.observer/filing/0001654954-24-000467.json","markdown":"https://secwatch.observer/filing/0001654954-24-000467.md","text":"https://secwatch.observer/filing/0001654954-24-000467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000467/0001654954-24-000467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000467/rmed_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:35:52.038019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9260b6e6c185f1bf7846fd73e9315b105bfe1b51","claim":"Catheter Precision, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $129,000 for the quarter and $442,000 for the year, net income net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year.","evidence_excerpt":"results of the fourth quarter and year ended December 31, 2023, include the following: · Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively. · Total cash on hand as of December 31, 2023, was approximately $3.6 million. · Total assets as of December 31, 2023, subject to adjustment, was $30.7","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000467/0001654954-24-000467-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$129,000 for the quarter and $442,000 for the year"},{"label":"Net income","value":"net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}